Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Please share Science & Enterprise

AI-Designed Antibodies for Start-Up Sought in Open Call

Computational biology illustration

An international consortium is seeking teams of scientists using algorithms to design new therapeutic antibodies, to form and fund a start-up company. . . . → Read More: AI-Designed Antibodies for Start-Up Sought in Open Call

European Life Science Venture Fund Raises €472M

Euro investments

A venture capital company raised €472 million ($US 548 million) for investments in life science and medical device start-ups in Europe. . . . → Read More: European Life Science Venture Fund Raises €472M

Crispr Licensed for Eye Disease Gene Therapies

Retinal gene therapy

A developer of inherited eye disease therapies is acquiring rights to the gene editing technology Crispr for treatments that work inside the eyes. . . . → Read More: Crispr Licensed for Eye Disease Gene Therapies

Precision Neuroscience Company Starts-Up, Raises $500M

Brain activity graphic

A new company is underway developing more precise therapies for psychiatric and neurodegenerative diseases based on genetics and data science. . . . → Read More: Precision Neuroscience Company Starts-Up, Raises $500M

Synthetic Antibody Company Goes Public in $230M Merger

Four fist bump

A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger

Foundation Plans $1B for Longevity Research

Older couple

A charitable foundation began work today supporting research on human longevity, with the goal of increasing lifespans to more than 120 years. . . . → Read More: Foundation Plans $1B for Longevity Research

Trial Underway Testing Cancer Drug as Covid-19 Therapy

SARS-CoV-2 and cell

A clinical trial enrolled and dosed its first participant testing an oral drug, initially designed to treat cancer, as a therapy for mild Covid-19 infections. . . . → Read More: Trial Underway Testing Cancer Drug as Covid-19 Therapy

Gene-Edited Treatments in Works for Safer Cancer Therapies

T-cells and cancer cells

A cancer center and biotechnology enterprise are developing gene-edited therapies working in the gut to reduce adverse effects from cancer immunotherapies. . . . → Read More: Gene-Edited Treatments in Works for Safer Cancer Therapies

Pharma, Synthetic Bio Companies to Find Antibody Therapies

DNA chip graphic

A pharmaceutical company and developer of synthetic genomic materials are collaborating on discovery of therapeutic antibodies to treat a range of diseases. . . . → Read More: Pharma, Synthetic Bio Companies to Find Antibody Therapies

Trial Shows Synthetic Antibody Slows Cognitive Decline

neurons

Results show a synthetic antibody reduces the rate of cognitive decline, one of two measures in a clinical trial of patients with mild to moderate Alzheimer’s disease. . . . → Read More: Trial Shows Synthetic Antibody Slows Cognitive Decline